Precision BioSciences, Inc. has taken a notable step in its growth strategy by announcing a stock offering aimed at raising funds to support its clinical programs. The company expects to issue 10,235,077 shares of its common stock at a price of $7.75 per share, along with pre-funded warrants to purchase an additional 5,893,964 shares. This move is significant as it reflects the company's commitment to advancing its PBGENE-HBV and PBGENE-DMD clinical programs.

According to the recent SEC filing dated November 9, 2026, the company anticipates net proceeds from this offering will enhance its cash runway, ensuring sufficient funds into the fourth quarter of 2029. This funding is crucial as it positions Precision BioSciences to reach key inflection points in its clinical development.

Company Overview

Precision BioSciences, Inc. is a biotechnology company incorporated in Delaware, primarily engaged in developing innovative therapies for genetic diseases. The firm operates under the SIC classification of Biological Products, (No Diagnostic Substances) [2836]. It trades on the Nasdaq under the ticker symbol DTIL. The company has recently filed various reports, including 8-K and 10-Q forms, indicating active engagement with investors and regulatory bodies.

Details from the Filing

The SEC filing highlights that the company entered into an underwriting agreement for the stock offering on November 5, 2026. The filing states, "The Company expects net proceeds from the Offering in addition to existing cash and cash equivalents, continued fiscal and operating discipline, and availability of its at-the-market facility will provide sufficient cash runway into the fourth quarter of 2029." This statement underscores the company's strategic planning and financial management.

Impact on Stakeholders

This offering may affect various stakeholders, including investors, employees, and competitors in the biological products industry. Investors may view this as a positive step towards funding critical clinical trials, while employees may anticipate increased job security and growth opportunities as the company expands its operations. Competitors will likely observe Precision BioSciences' moves closely, as this could impact market dynamics within the biological products sector.

What's Next?

The filing does not specify what happens next regarding the stock offering, but it indicates that the company is poised for significant developments in its clinical programs. Investors and market participants will be watching for further updates on the outcome of this offering and its implications for the company's future.